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Abstract 25 
Inflammation is an essential component of many lung diseases, including asthma, chronic 
obstructive pulmonary disease (COPD) or acute lung injury. Our purpose was to design efficient 
carriers for lung delivery of small interfering RNA (siRNA) targeting tumor necrosis factor (TNF-
 in an acute lung injury model. To achieve this goal, two different types of phosphorus-based 
dendrimers with either pyrrolidinium or morpholinium as terminal protonated amino groups were 30 
selected for their better biocompatibility compared to other dendrimers. Dendriplexes containing 
pyrrolidinium surface groups demonstrated a stronger siRNA complexation, a higher cellular uptake 
and enhanced in vitro silencing efficiency of TNF-in the lipopolysaccharide (LPS)-activated 
mouse macrophage cell line RAW264.7, compared to morpholinium-containing dendriplexes. The 
better performance of the pyrrolidium dendriplexes was attributed to their higher pKa value leading 35 
to a stronger siRNA complexation and improved protection against enzymatic degradation resulting 
in a higher cellular uptake. The superior silencing effect of the pyrrolidinium dendriplexes, 
compared to non-complexed siRNA, was confirmed in vivo in an LPS-induced murine model of 
short term acute lung injury upon lung delivery via nasal administration. These data suggest that 
phosphorous dendriplexes have a strong potential in lung delivery of siRNA for treating 40 
inflammatory lung diseases. 
Keywords 
siRNA; TNF-α; lung inflammation; dendriplex; phosphorous dendrimer; transfection efficiency, 
LPS 
  45 
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1 Introduction 
Inflammation is an essential component of many lung diseases such as asthma, chronic obstructive 
pulmonary disease (COPD) or acute lung injury (ALI)
1,2
. ALI and the acute respiratory distress 
syndrome (ARDS) are common causes of intensive care mortality 
3
. In ALI, resident and recruited 
alveolar macrophages play a key role in initiating and maintaining pulmonary inflammation 
4
. 50 
Alveolar macrophages from ALI patients have increased baseline and stimulated secretory levels of 
proinflammatory proteins, including certain cytokines and chemokines 
5
. Of the numerous 
cytokines, tumor necrosis factor (TNF-α) is believed to play a key role in the inflammation process 
6
. Current medicinal treatment of the inflammation involves anti-inflammatory drugs, such as 
glucocorticoids, which quite often result in systemic drug exposure and undesired side effects 
7
. 55 
Treatment based on small interfering RNA (siRNA) may therefore provide a more specific and less 
toxic therapy in which the inflammatory pathways leading to TNF- secretion can be targeted. One 
of the major obstacles limiting the use of siRNA as a drug is their low permeation across cell 
membranes due to their unfavorable physicochemical properties (high molecular weight and 
positive charge) and their poor stability in biological fluids. Thus, synthetic carriers, including 60 
nanocarriers using cationic lipids or cationic polymers e.g., polyethylenimine (PEI) or chitosan, 
have been designed for lung delivery of siRNA 
8,9
 as they protect them from enzymatic degradation 
and further facilitate their transmembrane delivery and release into the cytoplasm 
10
. In this work, 
we have applied a new family of dendrimers as siRNA carriers. Dendrimers are synthetic polymers 
characterized by a branched structure and a globular shape with high monodispersity and vast 65 
opportunities for surface tailoring as well as their ability to condense nucleic acids into 
nanoparticles 
11,12
. Indeed, dendrimers have been shown to be efficient siRNA delivery systems in 
vitro and in vivo in several studies, where mostly the commercially available polyamidoamine 
(PAMAM) dendrimers have been used 
13,14
. However, in very preliminary in vitro experiments, 
phosphorous dendrimers have been shown to be more efficient in cellular delivery of siRNA 70 
compared to PAMAM dendrimers 
15
. Phosphorous dendrimers have a backbone consisting of 
aminothiophosphates at every branching point. In addition, they possess intrinsic properties that are 
the easy regioselective functionalization of the core, the possibility to play with the 
hydrophilicity/hydrophobicity of the surface and of the core, the interior being hydrophobic, their 
biocompatibility and biodegradability as well as high thermal stability 
16–18
. Further, it has been 75 
shown that phosphorous dendrimers may exhibit anti-inflammatory properties 
19,20
. Indeed, 
incubation of a polyanionic phosphorous dendrimer with activated monocytes resulted in the up-
regulation of the expression of several anti-inflammatory cytokines, including interleukin (IL)-10 
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19–21
. The local administration to the lungs of dendriplexes carrying an antiTNF- siRNA can be 
considered to exert its effect directly on the inflamed tissue. Interactions with serum proteins that 80 
degrade siRNA after intravenous administration is mitigated as serum is absent on the air-side of 
the lung and nuclease activity is comparably low 
9,22,23
. 
For this study, two different cationic, phosphorous dendrimers of generation 3 (G3) were 
synthesized, functionalized with either cationic pyrrolidinium or morpholinium surface groups. 
These surface groups are secondary amines, which have both been considered for their excellent 85 
binding properties versus nucleic acids 
24,25
. The synthesized dendrimers were investigated as 
transfection agents for the delivery of siRNA directed against TNF-α, and the resulting dendriplexes 
were characterized and their performance assessed. An activated mouse macrophage cell line and a 
murine acute lung injury model were used for biological assessment of the prepared siRNA 
formulations. 90 
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2 Experimental Section 
2.1 Materials 
Phosphorous dendrimers were synthesized and characterized by 
1
H, 
13
C,  and 
31
P NMR. The 
phosphorus dendrimer of generation 3 (1G3) bearing 24 terminal P(S)Cl2  was synthetized as 95 
previously described
26
.  Grafting of amino pyrrolidine or aminomorpholine was conducted as 
reported for the grafting of other diamines
27
 and leads to dendrimers bearing 48 terminal cationic 
pyrrolidinium groups (DP) or 48 morpholinium groups (DM) (figure 1). Dicer substrate asymmetric 
duplex siRNA directed against TNF-α 14 was provided by Integrated DNA Technologies Inc. (IDT, 
Coralville, IA, USA) as dried, purified and desalted duplexes. The TNF-α siRNA consisted of the 100 
following sequences:  
Sense 5'-pGUCUCAGCCUCUUCUCAUUCCUGct-3', 
Antisense 5'-AGCAGGAAUGAGAAGAGGCUGAGACAU-3', where the lower case letters 
indicate 2'-deoxyribonucleotides, underlined capital letters represent 2'-O-methylribonucleotides 
and p is a phosphate residue (Mw 17,047 Da). Negative control sequences of siRNA (scrambled) 105 
were acquired from Eurogentec (Eurogentec, Angers, France). The exact sequence of the negative 
control siRNA was not disclosed by the supplier. Fluorescent dicer substrate siRNA labeled with 
the dye TYE™ 665 was also provided by IDT with a sequence directed against luciferase:  
Sense 5'-pGGUUCCUGGAACAAUUGCUUUUAca-3', 
Antisense 5'-UGUAAAAGCAAUUGUUCCAGGAACCAG-3'.  110 
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Figure 1.  Synthesis and chemical structures of cationic phosphorus dendrimers of generation 3: DP 
(pyrrolidinium end groups) and DM (morpholinium end groups).  
 
RNAse-free diethyl pyrocarbonate (DEPC)-treated water was used for dilutions, buffers and all 115 
solutions containing siRNA and dendrimers. The duplexes were re-annealed in duplex buffer 
consisting of 30 mM 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid (HEPES) and 100 mM 
potassium acetate prior to any formulation, as recommended by the supplier. All experiments were 
performed at 25 ºC in 10 mM HEPES buffer, pH 7.4 unless otherwise stated. Primers for PCR 
(Supplementary material, Table S1) were provided by Eurofins MWG Operon (Ebersberg, DE). 120 
Lipopolysaccharide (LPS) (γ-irradiated, <1% protein) was obtained from Sigma-Aldrich (St 
Quentin Fallavier, France), All additional chemicals used were obtained commercially and were of 
analytical grade. 
2.2 Acid-base titration 
The pKa value of each dendrimer was determined after titration. Each dendrimer was dissolved in a 125 
30 mL aqueous solution at a 0.2 mg/mL concentration. The solution was then adjusted to a pH 
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value of 10 using 1 M NaOH, and the pH was measured using a pH meter (Mettler Toledo, 
Viroflay, France). The solution was then titrated using 1 M HCl in 2 µl volume increments down to 
a pH value of 2 according to the volume of HCl added. From these curves the pKa value was 
estimated.  130 
2.3 Size and zeta potential measurements 
The average particle size (z-average) and polydispersity index (PDI) of the dendrimers were 
measured by dynamic light scattering (DLS), and the surface charge was assessed by zeta potential 
analysis (laser-Doppler electrophoresis). Measurements were performed using a Zetasizer Nano ZS 
(Malvern Instruments, Worcestershire, United-Kingdom) equipped with a 633 nm laser and 173° 135 
detection optics. Dendrimer solutions were prepared at 5.6 µM in 10 mM HEPES buffer and a 
volume of 1 ml was added to the cuvette for measurements. The Malvern DTS v.6.10 software 
(Malvern Instruments) was used for data acquisition and analysis, and a zeta potential transfer 
standard (−50 ± 5 mV, Malvern Instruments) was used to verify the performance of the instrument. 
2.4 Preparation of dendriplexes  140 
All dendriplexes were prepared at a nitrogen-to-phosphate (N/P) ratio (the molar charge ratio 
between the cationic dendrimer and the anionic siRNA) of 5, 10 or 20, respectively in 10 mM 
HEPES buffer. In brief, the dendrimer and siRNA solutions were prepared separately in a total 
volume of 100 µl, and 20 µl dendrimer solution was added to 80 µl of siRNA solution, followed by 
vortex mixing. The mixture was left at room temperature for 10 min to allow the complexes to 145 
form. The final concentrations of the mixtures were 5 µM for siRNA and 28, 56 112 µM for the 
dendrimers at N/P ratios of 5, 10, and 20, respectively. Further adjustment of the concentration was 
obtained by subsequently diluting in 10 mM HEPES buffer to obtain lower concentrations and by 
using filter centrifugation for up-concentrating the samples. Amicon Ultra-0.5 mL centrifuge tubes 
8 
 
(Thermo-Fisher, Villebon, FR) were used to centrifuge dendriplex dispersions at 11,740 g for 20 150 
min.  
2.5 Characterization of dendriplexes 
The z-average, polydispersity index (PDI) and the zeta potential of the dendriplexes were measured 
as described above for dendrimers. Measurements were performed on diluted samples at 500 nM 
and 2.8 µM siRNA and dendrimer, respectively. All samples were prepared in triplicate (n=3) and 155 
for each sample, a minimum of three measurements were performed. Gel electrophoresis was 
performed to assess the binding of siRNA to the dendrimers as dendriplexes. A total amount of 0.1 
nmol siRNA was used per well and the electrophoresis was carried out using 1% (w/v) agarose gels 
(Promega, Madison, WI, USA). The gels were run at 100 V for 20 min in Tris-borate-EDTA (TBE) 
buffer (pH 8.2) supplemented with 5 µL of 2.5 mg/mL ethidium bromide, and the siRNA bands 160 
were visualized using a MF-ChemiBIS gel imaging system (DNR Bio-Imaging Systems, Jerusalem, 
Israel).  
2.6 Cell culture 
The mouse macrophage cell line RAW264.7 was acquired from American Type Culture Collection 
(ATCC), and was used at an unspecified passage number in all cell-based experiments. The cells 165 
were cultured using Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma Aldrich, St. Louis, 
MO, USA) supplemented with 10% (v/v) fetal bovine serum (PAA Laboratories, Pasching, 
Austria), 100 U/ml penicillin, and 100 µg/ml streptomycin. The cells were incubated in an 
atmosphere of 5% CO2 and 95% O2 at 37 °C and sub-cultured twice a week by scraping the cells 
from the culture flask and re-suspending them in fresh culture medium. The cells were used at 80% 170 
confluence between passages 5-10. 
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2.7 Cell viability 
The viability of the RAW264.7 cellswas measured using the 3-(4,5-dimethylthiazol-2-Yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Cells were detached from the surface of culture flasks, 
pooled, counted, adjusted to the right concentration, and seeded in 96-well plates at a density of 8 × 175 
10
3
 cells per well and left overnight. Subsequently, they were incubated with dendriplexes (N/P 
ratio of 5) at different concentrations for 24 h and the medium was replaced with fresh medium. For 
each well, 10 µl of MTT-solution [5mg/ml in phosphate-buffered saline (PBS), pH 7.4] was added 
to 100 μl of cell culture medium. The plate was incubated for 2 h at 37 °C to allow the 
transformation of MTT to formazan crystals. The medium was then removed, and 200 µl of 180 
dimethylsulfoxide was added to each well to dissolve the MTT formazan crystals. Absorbance was 
spectrophotometrically detected at a wavelength of 570 nm using a microplate reader (FLUOstar 
OPTIMA, BMG labtech, Champigny-sur-Marne, France). The viability of the cells was calculated 
as percentage by comparing the absorbance from cell suspensions exposed to dendriplex samples 
with those from corresponding untreated control cell suspensions. The half-maximal inhibitory 185 
concentration (IC50) was determined based on the dose-response curve using linear regression and 
estimated from the fitted line.  
2.8 Cell uptake  
Flow cytometry and fluorescence microscopy were employed to assess the cellular siRNA uptake 
and intracellular distribution in RAW264.7 cells. For flow cytometry studies, the cells were cultured 190 
in 12-well plates in full culture medium at a density of 5 × 10
5
 cells per well. The cells were treated 
with fluorescent siRNA, either non-complexed or in dendriplexes (N/P ratio of 5) at a concentration 
of 100 nM fluorescent siRNA for 0.5-4 h before resuspension and analysis by flow cytometry using 
an Accuri C6 (BD biosciences, Franklin Lakes, NJ, USA). These measurements were used to 
determine the relative uptake, the ratio between the mean fluorescence intensity (MFI) of the treated 195 
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samples, and the non-treated negative control, expressed in arbitrary units. For fluorescence 
microscopy, cells were cultured in chambered coverslips, µ-Slide 8 well (Ibidi, Planegg, Germany), 
at a density of 5 × 10
4
 cells per well. The cells were treated with fluorescent siRNA, either non-
complexed or as dendriplexes (N/P ratio of 5) at a concentration of 100 nM fluorescent siRNA for 4 
h and subsequently washed with PBS and fixed using 4% (v/v) paraformaldehyde. Microscopy 200 
images were captured at a 63x magnification with a Zeiss LSM 510 (Carl Zeiss, Jena, DE) 
fluorescence microscope equipped with a 1 mW helium-neon laser and a plan-apochromat 63X 
objective lens (numerical aperture 1.40, oil immersion). Differential interferential contrast (DIC) 
images were collected simultaneously. The TYE™ 665 dye was excited using a 633 nm laser 
illumination and collected with a 650 nm long pass emission filter. The pinhole was set at 1.0 Airy 205 
unit (0.8 µm optical slice thickness). Twelve bit numerical images were acquired with LSM 510 
software version 3.2 (Carl Zeiss). 
2.9 Cell transfection  
Transfection experiments were performed essentially as previously described 
14
. In brief, cells were 
seeded in 6-well culture plates at a density of 1 × 10
6
 cells per well in full culture medium and left 210 
overnight. The dendriplexes were prepared as described above (N/P ratio of 5) and 100 µl 
dendriplex suspension was added to each well at different dilutions to achieve final siRNA 
concentrations of 6, 12, 25, 50 and 100 nM, respectively, in the wells, and incubated for 24 h. Three 
hours prior to harvesting, 100 µl PBS containing LPS was added to each well to obtain a final LPS 
concentration of 5 ng/ml. Positive controls for inflammation response were not treated with siRNA 215 
or dendrimer but were treated with LPS while negative controls were incubated with PBS. At 
harvesting, the culture medium was removed from the wells and the cells were washed with PBS 
and subsequently 1 ml cold TRIzol (Thermo Fisher, Villebon-sur-Yvette, France) was added to 
each well, and the cells were loosened by scraping. The contents of each well was mixed by 
pipetting, transferred to centrifuge tubes and kept on ice.  220 
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RNA extraction was performed from the TRIzol-suspended cell homogenates following the 
instructions of the protocol provided with TRIzol reagent. The total RNA content of the extract 
samples was quantified using a UV spectrophotometer, Biomate 3 (Thermo Fisher) with a TrayCell 
fiber-optic ultra-micro cell (Hellma Analytics, Paris, France) and quality control of the RNA 
samples was performed with a RNA LabChip, using an Agilent 2100 Bioanalyzer (Agilent, Santa 225 
Clara, CA, USA). Reverse transcription of 1 µg RNA samples was done using a mixture of primers 
applying an iScript cDNA Synthesis Kit (Biorad, Hercules, CA, USA). The cDNA samples were 
diluted 1:10 in RNAse-free water and stored at -80°C. All RNA samples showed a 260/280 ratio 
between 2.0-2.2 and an RNA integrity number (RIN) number between 9 and 10. 
The knockdown of TNF-α mRNA was assessed by real time reverse transcription polymerase chain 230 
reaction (RT-PCR) essentially as previously described 
14
. All PCR reactions were performed in 
duplicate in a total reaction volume of 20 µl using 10 µl of SsoAdvanced Universal SYBR Green 
Supermix (Biorad, Hercules, CA, USA), 5 µl cDNA working solution (1:10 dilution) and 0.5 µM of 
forward and reverse primers (Table ST1, supplementary material). Real-time PCR was performed 
using a C1000 Thermal Cycler instrument with a CFX96 Real-Time System (Biorad) with the 235 
following cycling conditions: An initial denaturation step at 95 °C for 5 min, followed by 35 cycles 
of denaturation at 95 °C for 10 s, annealing at 60 °C for 10 s, and elongation at 72 °C for 10 s. The 
CFX manager software 3.0 (Biorad) was used for crossing point (CP) analysis, and the values were 
normalized against the average of the two reference genes, glucoronidase b (GUSb) and ribosomal 
protein, large P2 (RPLP2). These reference genes were chosen from a screening test of eight 240 
reference candidates, which showed that the optimal number of reference targets is two or three 
(geNorm V < 0.15) where good reference target stability is achieved. Gene knockdown data is 
presented as the relative gene expression compared to the positive control (LPS-treated cells). 
2.10 In vivo studies 
2.10.1 Mice 245 
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Experiments were conducted according to the European rules (86/609/EEC and 2010/63/EU) and 
the Principles of Laboratory Animal Care and national French legislation (Decree No. 2013-118 of 
February 1, 2013). All techniques/procedures were refined to provide for maximal comfort and 
minimal stress to the animals. Mice were housed in groups of four with access to water and food ad 
libitum and kept at constant temperature (19-22°C) and relative humidity (45-65%). Female CD-1 250 
mice were purchased from Envigo (Gannat, France), and all experiments were performed using 
mice at the age of 6 to 8 weeks. 
2.10.2 Lung inflammation model 
A widely used protocol for acute LPS-induced lung inflammation 
28–30
 was adjusted for CD-1 mice. 
The mice were anesthetized by intraperitoneal (i.p.) injection of 200 µl Ketamine (3.5 255 
mg/ml)/Xylazine solution (5 mg/ml), and the animals were monitored until disappearance of the 
plantar reflex. Using a pipette, the LPS solution (3.2 mg/kg) was administered to the mice by nasal 
administration (1.2 µl LPS solution/g of mouse weight) by placing the mice on their backs and 
allowing them to inhale the solution through the nostrils. Subsequently, the mice were allowed to 
wake up and were monitored over the next days. For bronchoalveolar lavage (BAL), the mice were 260 
euthanized via an overdose of pentobarbital (i.p. injection of 200 µl 20 mg/ml pentobarbital 
solution), and the trachea was exposed from an incision and cannulated with a 22-gauge catheter 
(BD biosciences). Subsequently, BAL was performed by flushing the lungs with seven times 0.3 ml 
PBS, and the first two lavages (collected separately) were used for protein quantification and cell 
counting/differentiation, whereas the last five lavages were used only for cell 265 
counting/differentiation. The BAL was centrifuged at 400g for 10 min, the supernatant was stored at 
-20 °C for protein quantification, and the pellets were pooled and resuspended in fresh PBS.  
 
2. 10.3 Experimental design  
Mice were dosed with the siRNA as a prophylactic treatment prior to inducing inflammation in their 270 
lungs (Figure 2). Dendriplexes (N/P ratio of 5) were administered via nasal administration as 
13 
 
described for the LPS administration. They were given at an siRNA concentration of 2.0 mg/kg in 
an average volume of 30 µl 24 h prior to administration of LPS. The mice were assessed 4 and 72 h 
after the LPS challenge, and a minimum of five mice were included in each treatment group. They 
were dosed either with siRNA targeting TNF-α or non-coding scrambled siRNA (SCR). Positive 275 
controls were pretreated with PBS, and were subsequently dosed with LPS. Negative controls were 
pretreated with PBS and were subsequently given PBS. 
 
Figure 2. Schematic overview of the timeline in the animal experimental model and the subsequent 
sample analysis. 280 
 
2.10.4 Cell counting and differentiation 
The total cell number in each lavage was counted using KOVA Glasstic hemocytometer slides, 
(KOVA international, Amsterdam, The Netherlands). For each animal, the ratio between 
neutrophils and macrophages (N/M ratio) was calculated based on counting a total of 300 cells. 285 
 
2.10.5 Protein quantification 
Protein levels in the BAL were quantified using the Cytometric Bead Array - Mouse inflammation 
kit (BD biosciences), and the IL-6, IL-10, Interferon-γ (IFN-γ) and TNF-α protein levels in the BAL 
were measured. BAL supernatants were stored at -20 °C and were used directly or diluted (1:3, v/v) 290 
14 
 
in assay diluent from the kit, and the samples were prepared following the instructions in the 
protocol of the kit. The BAL protein levels were finally quantified by flow cytometry using an 
Accuri C6) with 2000 ROI counts measured for each sample. All samples were prepared in 
duplicates and analyzed using the BD Accuri C6 software. 
2.11 Statistics 295 
Data reported for the cell studies are given as mean values ± SD. Data reported for the in vivo 
studies are given as mean values ± SEM. The in vitro and in vivo data were all based on 
independent replicates with each sample set consisting of samples prepared in different days. 
Statistical significance was confirmed by using the two-tailed and unpaired Student's t-test. 
Statistical analyses were performed by using the student’s t-test. The level of significance was set at 300 
p < 0.05. 
3 Results and discussion 
3.1 Physicochemical characterization of dendrimers and dendriplexes 
All dendriplexes have a mean size between 120-190 nm and a PDI between 0.27-0.44 (Figure 3, A 
and B) whereas the hydrodynamic diameter of both dendrimers was around 3 nm (Table 1). Their 305 
polydispersity is consistent with what is reported in the literature for siRNA complexes self-
assemble into larger aggregates 
31
. No clear correlation between the N/P ratio and the resulting 
hydrodynamic diameter and PDI of the dendriplexes was observed. Similar size and PDI of DP and 
DM dendriplexes were measured. A positive zeta potential was observed for all dendriplexes, 
indicating an overall positive surface charge (Figure 3C). The zeta potential increased as a function 310 
of N/P ratio due to the higher charge ratio resulting in better siRNA condensation and higher 
surface charge. Higher zeta potential values were generally observed for DP dendriplexes than for 
DM dendriplexes at all N/P ratios. This is related to the difference in pKa value of the two 
15 
 
dendrimers. DP and DM dendrimers have a pKa value of 8.1 and 7.1, respectively (Table 1). 
Therefore at a pH of 7.4 in HEPES buffer, DP dendrimers are more ionized than DM dendrimers 315 
resulting in higher positive zeta potential values. 
 
Figure 3. Z-average (A), polydispersity index (PDI) (B) and zeta potential (C) of DP and DM 
dendriplex aggregates prepared in HEPES buffer (10 mM, pH 7.4). Data points represent mean 
values ± SD (n ≥ 3). Statistically significant differences between DP and DM dendriplexes are 320 
indicated: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Agarose gel electrophoresis of dendriplex 
aggregates (0.9µg siRNA loading) (D). 1: Non-complexed siRNA; 2-4: DP dendriplex aggregates at 
N/P ratios of 5, 10, and 20, respectively, 5-7; DM dendriplex aggregates at N/P ratios of 5, 10 and 
20, respectively.   
 325 
Gel electrophoresis studies give an indication of the binding affinity between siRNA and the 
dendrimers. These studies show stronger binding between siRNA and dendrimers at higher N/P 
ratios for both DP and DM dendrimers confirming the zeta potential observations (Figure 3D). 
Binding with siRNA was substantially different for DP and DM dendrimers with DP dendriplexes 
retaining their siRNA, while DM dendriplexes mostly disassociated upon electrophoresis, 330 
16 
 
indicating stronger binding for DP dendriplexes. This result is again related to the difference in 
ionization of the dendrimers due to their different pKa values. As complexation is performed at a 
pH value slightly above the pKa value of DM dendrimers, only a few amine groups are charged and 
the binding is weaker than for DP dendrimers. Given the results obtained at different N/P ratios, 
biological studies were carried out at an N/P ratio of 5 to maximize the amount of siRNA associated 335 
to the dendriplexes while providing dendriplexes with comparable hydrodynamic size and siRNA 
binding affinity.  
3.2 Cytotoxicity and cell uptake of dendriplexes 
The cell viability was evaluated by measurement of the mitochondrial activity using the MTT assay 
on RAW 264.7 cells to determine the maximal tolerated concentration for further transfection 340 
experiments. Viability studies showed that dendriplexes prepared using the two different types of 
dendrimers possess significantly different toxicity profiles (Figure 4A). DM dendriplexes did not 
show any notable reduction in cell viability in the studied concentration range (IC50 > 15 µM 
siRNA). In contrast, DP dendriplexes exhibited a reduction in cellular viability as a function of 
siRNA concentration, with a calculated IC50 siRNA concentration of 470 nM, corresponding to a 345 
dendrimer concentration of 41 µg/ml. A similar toxicity profile was observed for the non-
complexed dendrimers (Figure S1). Also here, the DP dendrimers showed significantly higher 
toxicity compared with the DM dendrimers, which did not have any measurable toxicity. The higher 
toxicity of DP dendriplexes measured in this study could partly be related to their higher surface 
charge, or perhaps due to higher cell permeation and a higher degree of interaction with cellular 350 
components. The assessment of cytotoxicity again highlights the pronounced difference between the 
two types of dendrimers with only slightly different surface functional groups. The cytoxicity 
measured for the DP dendriplexes (IC50 = 41 µg/ml) is comparable to that observed for other 
cationic polymer-based transfection agents, e.g., PEI (IC50 = 40 µg/ml) and poly-L-lysine (PLL) 
(IC50 = 45 µg/ml) 
32
. For all subsequent cell studies, siRNA concentrations lower than 100 nM, 355 
17 
 
corresponding to dendrimer concentrations of 15 µg/ml, were used in order to remain below the 
minimal toxic concentration for the DP dendriplexes (80%). 
The cell uptake kinetics of non-complexed siRNA and dendriplexes was measured using flow 
cytometry (Figure 4B). For non-complexed siRNA, as expected, the relative uptake remained very 
low over time. For the DM dendriplexes, a very modest yet statistically significant uptake of siRNA 360 
was observed. For the DP dendriplexes, a significantly higher uptake of siRNA was demonstrated. 
The MFI of cells incubated with DP dendriplexes was five times higher than the MFI of cells 
incubated with non-complexed siRNA after 4 h incubation, while only a two-fold increase was 
observed for cells incubated with DM dendriplexes. 
 365 
Figure 4. Cell viability of RAW 264.7 cells as a function of siRNA concentration, measured after 
24 h incubation with dendriplexes, and toxicity values for DP and DM dendriplexes (A). Cellular 
uptake of siRNA in RAW 264.7 cells as a function of incubation time, measured as siRNA 
fluorescence intensity using flow cytometry (B). Data points represent mean values ± SD (n ≥ 3). 
Statistical significance: * p < 0.05, ** p < 0.01. 370 
To further investigate siRNA uptake, cells incubated with non-complexed siRNA or dendriplexes 
for 4 h were observed by confocal/DIC microscopy. Observations corroborated the flow cytometry 
measurements (Figure 5), and were verified by z-stack images (not shown). Cells incubated with 
non-complexed siRNA did not show any detectable fluorescence above background levels, proving 
that no cell internalization of the siRNA occurred (Figure 5B). Cells incubated with DM 375 
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dendriplexes showed a small amount of the siRNA internalization, while the majority of the siRNA 
was adsorbed on the surface of the cells (Figure 5C). However, cells incubated with DP 
dendriplexes showed internalization of siRNA in the cells with siRNA distributed within the 
cytoplasm (Figure 5D). 
The images indicate that DP dendriplexes are mainly taken up by cells whereas DM dendriplexes 380 
mainly tend to adhere to the outer surface of the cell membrane as aggregates. This indicates better 
internalization of DP dendriplexes compared with DM dendriplexes, which also confirms the 
observations from the flow cytometry measurements. The higher uptake observed for the DP 
dendriplexes could be explained by their stronger positive charge and better stability. DM 
dendriplexes most probably dissociate in the cell culture medium before aggregating on the cell 385 
surface. These results are in agreement with the stronger binding observed for DP dendriplexes than 
for DM dendriplexes and possibly also their higher net surface charge, which has been shown in 
several studies to result in higher cellular uptake
33–35
. The cell uptake results could also explain the 
difference of toxicity observed between the two dendriplexes. Indeed constructs with high positive 
charge have been reported to results in some cytotoxicity 
34
. As DM dendrimers lead to a lower 390 
internalization, the mitochondrial activity is less affected and the resulting viability measured by 
MTT-assay remains higher. 
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Figure 5. Representative image of the cellular uptake of dendriplexes in RAW 264.7 cells after 4 h 395 
of incubation. Overlay of a bright field and fluorescence image for untreated cells (A) and cells 
incubated with non-complexed siRNA (B), DM dendriplexes (C) and DP dendriplexes (D). 
 
3.3 In vitro inhibition of TNF- by dendriplexes in LPS treated macrophages 
Cells treated with the dendriplexes containing TNF-α siRNA and subsequently activated with LPS 400 
were assessed at the mRNA level using RT-PCR (Figure 6). The relative TNF-α expression levels 
were lower for all TNF-α based samples compared with the corresponding scrambled siRNA 
samples. Non-complexed TNF-α siRNA showed 28 % inhibition, compared with the control, and a 
26 % inhibition compared with scrambled siRNA, both statistically significant (p < 0.05). The DM 
dendriplexes with TNF-α siRNA showed 34 % inhibition, compared with the control, and 33% 405 
inhibition, compared with scrambled siRNA, which were statistically significant (p < 0.05). The DP 
dendriplexes with TNF-α siRNA showed a rather substantial inhibition of 74 %, compared with the 
control, and a 50% inhibition, compared with scrambled siRNA, which were also statistically 
significant (p < 0.01). 
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Dose-response studies were performed for DP (Figure 6B) and DM (Figure 6C) dendriplexes in the 410 
6-100 nM siRNA concentration range to assess the influence of the siRNA concentration on the 
gene inhibition, and ascertain that the observed effects were specific. For both DM and DP 
dendriplexes, the gene silencing was concentration-dependent. DM dendriplexes were shown to 
provide significant TNF-α knockdown from 50 nM siRNA and up while DP dendriplexes were 
shown to provide significant TNF-α knockdown from 25 nM siRNA and up. For both dendriplexes 415 
the highest dose (100 nM siRNA) was below the toxic level of dendriplexes for the cells. The 
transfection efficiency data correlates well with the observations from the cell uptake study, where 
it was demonstrated that DP dendriplexes result in higher cell internalization compared with DM 
dendriplexes and non-complexed siRNA. The higher silencing obtained with DP dendriplexes can 
thus be explained by their higher cell uptake and their higher stability and surface charge. Although 420 
DM dendriplexes did not indicate convincing cell uptake and structural stability, the nevertheless 
demonstrated a significant silencing of TNF-α expression. It was similar for the non-complexed 
siRNA, which showed a modest  
 
 425 
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Figure 6. Dendriplex-mediated TNF-α mRNA silencing in RAW 264.7 cells. Normalization to LPS-treated 
cells (Control +) without siRNA was performed, and results denote the TNF-α mRNA expression level 
relative to transfection with negative control siRNA (referred to as scrambled (SCR) siRNA). (A) Samples 430 
corresponding to an siRNA concentration of 100 nM and an N/P ratio of 5, (B) Dose-dependent TNF-α 
mRNA silencing with DP dendriplexes, and (C) Dose-dependent TNF-α mRNA silencing with DM 
dendriplexes. Results denote the means ± SD (n ≥ 3). Statistical significance: * p < 0.05, ** p < 0.01. 
 
but significant silencing of TNF-α expression at the highest concentration, despite low cellular 435 
uptake. This could indicate that only a small fraction of cellular siRNA uptake is sufficient to 
provide a silencing effect. 
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3.4 Modulation of the inflammation by dendriplexes in a murine acute lung injury model 
An ALI model was used to assess the efficacy of the dendriplex formulations in vivo. LPS-induced 
ALI is considered one of the most important and applicable in vivo models to study molecular 440 
mechanisms and potential therapies for inflammation-associated lung injury as described 
36
. In 
humans, once a patient develops lung injury, the best known strategy is supportive care 
37
. 
However, many therapeutic agents have demonstrated a reduced efficacy, in part due the delay in 
initiating the therapy several days after the onset of lung injury 
37,38
. This is why we intentionally 
decided to pretreat animals prior to administration of LPS, as a prophylactic treatment, and this is 445 
believed to represent the optimal therapeutic scheme. 
The method for nasal instillation of the liquid suspensions was validated by administering a trypan 
blue solution to the mice and subsequently evaluating the deposition in the lungs and stomach. The 
lungs were entirely stained with trypan blue while the stomach did not show any dye, which 
indicates that most of the dye was delivered to the lungs (data not shown). The total cell count of 450 
the BAL indicates strong cell recruitment within 24 h after LPS challenge and is subsequently 
reduced as seen in the following time points (Figure S2A). The same trend was observed for the 
neutrophil-to-macrophage (N/M) ratio where neutrophil recruitment could be measured already 
after 4h. This also highlights that the majority of the subsequent cell recruitment observed occurs 
from the neutrophils (Figure S2B). Similar observations were made in other studies using intranasal 455 
instillation and LPS to assess therapeutic efficacy 
39,40
 
The cytokine profiles measured in the BAL after LPS challenge showed that the TNF-α levels 
(Figure S3) are very high 4 h after the animals are challenged with LPS and subsequently decrease 
over the next 3 days until they return to normal levels (32 pg/ml) after 7 days. A large increase was 
also observed for IL-6, IFN-ɣ and IL-10, for which the cytokine levels in the lungs were either 460 
sustained (IL-6, IL-10) or increased progressively (IFN-ɣ), and for the latter maximum levels were 
reached at day 3 after LPS challenge, followed by a decrease to normal levels at day 7. Additional 
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inspection of the mice showed a significant reduction in weight (approx. 10%) and lack of 
grooming in the first three days following LPS challenge (data not shown).  
Cytokine levels were compared for mice treated with LPS (Control +) and mice treated with non-465 
complexed dendrimers in solution, as well as untreated mice (Control -) and were evaluated in order 
to assess the potential inflammatory response of the non-complexed dendrimers. Both dendrimers 
showed a small response for TNF-α, which was minor compared with the effect of LPS, yet 
significantly higher than the negative control, meaning that the dendrimers resulted in a small 
inflammatory up-regulation (Figure S4A). No visible effect was observed for IL-6 and IFN-ɣ 470 
relative to the negative control (Figure S4A and S4B). However, both dendrimers experienced a 
slight increase in their IL-10 levels compared with the negative control indicating a small anti-
inflammatory response by the dendrimers (Figure S4D). 
The total BAL cell count was assessed for the different treatment conditions at 4 and 72 hours after 
LPS challenge. The cell population was not significantly different after 72 h (Figure S5A). The 475 
N/M ratio of the BAL for the different treatment conditions at 72 after LPS challenge was also 
assessed (Figure S5B). It was shown that the N/M ratio was lower for animals receiving a treatment 
containing anti-TNF-α treatment, although the differences in N/M ratio were not statistically 
significant. Yet, this could indicate a higher relative neutrophil recruitment for the positive control 
than for treated animals, which could also indicate a lower level of inflammation in the treated 480 
animals. Cytokine levels in the BAL were measured at different time points (4 and 72 h) after 
siRNA pre-treatment followed by LPS challenge. The siRNA dose was administered, based on 
previous pulmonary siRNA delivery studies (0.6-3 mg/kg siRNA administered) 
41–43
, to ensure a 
sufficient level to observe a potential therapeutic effect. An siRNA dose of 2 mg/kg was chosen. 
The TNF-α protein levels measured 4 h after LPS challenge (Figure 7A) show that all treatments 485 
containing TNF-α siRNA resulted in a reduction in the TNF-α expression, compared with the 
corresponding treatments containing scrambled siRNA. The strongest inhibition was observed for 
DP TNF-α (55 %) compared to non-complexed TNF-α siRNA (17 %). The specificity of this 
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inhibition was demonstrated by the weakest effect of the scrambled siRNA delivered either non-
complexed or by dendriplexes. DM TNF-α showed a slight increase in the TNF-α protein 490 
expression level, compared with the positive control confirming the lack of efficiency of these 
dendriplexes as shown in vitro. 
Measurements of other cytokine levels show that the TNF-α based siRNA also has an influence on 
these, which is expected, as their regulation is interdependent. Significantly increased IL-10 protein 
levels were observed for DP TNF-α (18 fold increase, Figure 7D) compared with the positive 495 
control at 4 h after LPS administration. In contrast, the DM dendriplexes did not affect the BAL IL-
10 level. This indicates that the DP TNF-α results in an anti-inflammatory response immediately 
after administering LPS. A substantial increase in the IL-6 protein secretion was observed for DP 
TNF-α (four-fold increase) compared with the positive control at 4 h after LPS administration 
(Figure 7C). The influence of non-complexed DP dendrimer on the cytokine expression was 500 
investigated by administering non-complexed DP dendrimer with a subsequent LPS challenge 
(Figure S6). It was observed, 4 h after LPS administration, that the non-complexed DP dendrimer 
resulted in an increase in IL-6 and IL-10, much lower than the secretion due to DP TNF-α and 
without any change in the production of TNF-α. The same trend is observed with scrambled-
associated dendriplexes. If an increase in IL-10 results from anti-inflammatory effects, IL-6 should 505 
be downregulated as this is the case for TNF-α. We believe that IL-6 upregulation is due either to 
DP or to the specific sequence of siRNA, or both. Many authors have demonstrated that IL-6 in the 
murine LPS-induced lung injury model displays anti-inflammatory properties 
44,45
 and could 
contribute to reducing TNF-α to a certain extent as this was demonstrated on the same model after 
intratracheal administration of IL-6
46
. Although TNF-α and IL 6 return to very low levels 72 h after 510 
LPS challenge (Figure 8A and C), DP TNF-α siRNA still induces a strong inhibition of 44% for 
TNF-α compared with the positive control, much higher than non-complexed TNF-α siRNA or DM 
TNF-α. This sustained efficiency, three days following the onset of lung inflammation, suggests a 
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clear and efficient silencing effect provided by the siRNA. At 72 h, IL-6 levels had decreased for 
both DP-TNF-α and scrambled associated dendriplexes (Figure 8C). 515 
Finally, IFN-ɣ, a pro-inflammatory cytokine, was slightly reduced for mice treated with DP 
dendriplexes and non-complexed siRNA compared with the positive control at 4-h after LPS 
administration but not in a significant manner, which is normal since the kinetics of secretion of 
IFN-ɣ is slowed down compared to the other cytokines (Figure 7 D). The overall trend of the 
cytokine levels indicates an anti-inflammatory effect of DP TNF-α compared with the positive 520 
control, induced by the effective transfection with anti-TNF-α siRNA. Unlike observations made at 
4 h, a considerable inhibition of IFN-ɣ levels was observed for dendriplexes compared with the 
positive control and compared with non-complexed siRNA (Figure 8B). Also a ten-fold increase in 
the INF-ɣ levels was observed from 4 h to 72 h following LPS challenge whereas all other 
cytokines studied decreased in their levels over the same period.  525 
From the in vivo assessment of the performance of the siRNA-loaded dendriplexes it can be 
established that the DP dendriplexes provided a more efficient silencing of TNF-α as well as a 
better anti-inflammatory regulation of other cytokines involved, compared with DM dendriplexes 
and non-complexed siRNA. This correlates well with the findings from in vitro transfection studies 
where the same trend was observed. The superior performance of DP dendriplexes is explained by 530 
the better ability of DP dendrimers to form stable complexes with siRNA therefore leading to a 
higher internalization in macrophages, which plays a key role in the production of TNF-α, a strong 
proinflammatory cytokine. 
 
 535 
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Figure 7. Cytokine concentration in BAL of mice challenged with LPS 24 h after administration of siRNA 
treatment, and euthanized 4 h after the LPS challenge, followed by extraction of BAL. Control - and Control 
+ denote untreated and LPS-treated mice, respectively. Data points represent mean values ± SEM. n ≥ 5. 
Statistical significance: * p < 0.05, ** p < 0.01, and *** p < 0.001. 540 
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Figure 8. Cytokine concentration in bronchoalveolar lavage of mice challenged with LPS 24h after 
administration of siRNA treatment and euthanized 72h after LPS challenge for extraction of bronchoalveolar 545 
lavage. Control - and Control + denote untreated and LPS treated mice, respectively. Error bars show SEM. 
N ≥ 5. Statistical significance: * P < 0.05, ** P < 0.01, *** P < 0.001. 
5. Conclusion 
In this study, siRNA therapeutics was assessed for the treatment of acute inflammation, which was 
achieved both in vitro and in vivo. Major inhibition of TNF-α was obtained by means of a cationic 550 
phosphorous dendrimer containing pyrrolidinium and binding efficiently anti-TNF-α siRNA. The 
obtained dendriplexes are highly efficient in delivering siRNA to LPS-activated macrophages. After 
intranasal administration, TNF- inhibition resulted in a strong anti-inflammatory effect as 
demonstrated by modulation of all other cytokines involved in the inflammation process. 
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Table 1. Physicochemical properties of cationic phosphorous dendrimers 
Dendrimer Surface group Primary 
amines 
MW 
(g/mol) 
pKa Hydrodynamic 
diameter (nm) 
DP Pyrrolidinium 48 16188.11  8.1 2.7 
DM Morpholinium  48 16956.06 7.1 2.9 
 
 
 
